Profil bibliographique

Meret Martin‐Facklam

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

44Publications signalées

2043Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Pharmacogenetics and Drug MetabolismLung Cancer Treatments and MutationsPharmaceutical Practices and Patient OutcomesAmino Acid Enzymes and MetabolismNeuroscience and Neuropharmacology Research

Publications récentes

Accès ouvert 2025 articleOpenAlex

PD‐1‐Cis IL‐2R Agonism Determines the Predicted Pharmacological Dose Range for the Immunocytokine Eciskafusp Alfa (PD1‐IL2v)

Lucy Hutchinson, Thomas D. Lewin, Laura Lauener, Meret Martin‐Facklam et autres

3 citationsCPT Pharmacometrics & Systems Pharmacology

Accès ouvert 2025 erratumOpenAlex

Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials

Gennaro Pagano, Dylan Trundell, Tanya Simuni, Nicola Pavese et autres

0 citationsnpj Parkinson s Disease

Accès ouvert 2025 articleOpenAlex

Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab

Kirsten I. Taylor, Florian Lipsmeier, Marzia A. Scelsi, Ekaterina Volkova-Volkmar et autres

14 citationsnpj Digital Medicine

Accès ouvert 2024 articleOpenAlex

Characterization of anti-drug antibody responses to the T-cell engaging bispecific antibody cibisatamab to understand the impact on exposure

Gregor P. Lotz, A. H. Lutz, Meret Martin‐Facklam, Andre Hansbauer et autres

8 citationsFrontiers in Immunology

Accès ouvert 2024 articleOpenAlex

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Neil H. Segal, Ignacio Melero, Víctor Moreno, Neeltje Steeghs et autres

71 citationsNature Communications

Accès ouvert 2021 articleOpenAlex

Managing the Impact of Immunogenicity in an Era of Immunotherapy: From Bench to Bedside

Katharine Bray‐French, Katharina Hartman, Guido Steiner, Céline Marban-Doran et autres

32 citationsJournal of Pharmaceutical Sciences

Accès ouvert 2018 articleOpenAlex

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

Joseph Jankovic, Ira Goodman, Beth Safirstein, Tonya Marmon et autres

301 citationsJAMA Neurology

2018 articleOpenAlex

Results from a phase 1b multiple ascending-dose study of PRX002/RG7935, an Anti-alpha-synuclein monoclonal antibody, in patients with Parkinson’s disease

Joseph Jankovic, Ira Goodman, Beth Safirstein, Dale B. Schenk et autres

4 citationsParkinsonism & Related Disorders

2017 conference-paperOpenAlex

Human Activity Recognition from Sensor-Based Large-Scale Continuous Monitoring of Parkinson’s Disease Patients

Wei‐Yi Cheng, Alf Scotland, Florian Lipsmeier, Timothy Kilchenmann et autres

55 citations

Accès ouvert 2017 articleOpenAlex

Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities

Stephen Fowler, Peter N. Morcos, Yumi Cleary, Meret Martin‐Facklam et autres

44 citationsCurrent Pharmacology Reports

2016 articleOpenAlex

Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects

Peter N. Morcos, Elena Guerini, Neil Parrott, Georgina Dall et autres

49 citationsClinical Pharmacology in Drug Development

2016 articleOpenAlex

Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects

Peter N. Morcos, Neil Parrott, Ludger Banken, Carsten Timpe et autres

11 citationsClinical Pharmacology in Drug Development

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.